ZA923557B - Composition of angiotensin-II receptor antagonists and calcium channel blockers - Google Patents

Composition of angiotensin-II receptor antagonists and calcium channel blockers

Info

Publication number
ZA923557B
ZA923557B ZA923557A ZA923557A ZA923557B ZA 923557 B ZA923557 B ZA 923557B ZA 923557 A ZA923557 A ZA 923557A ZA 923557 A ZA923557 A ZA 923557A ZA 923557 B ZA923557 B ZA 923557B
Authority
ZA
South Africa
Prior art keywords
angiotensin
composition
receptor antagonists
calcium channel
channel blockers
Prior art date
Application number
ZA923557A
Other languages
English (en)
Inventor
Pancras Chor Bun Wong
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Publication of ZA923557B publication Critical patent/ZA923557B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA923557A 1991-05-15 1992-05-15 Composition of angiotensin-II receptor antagonists and calcium channel blockers ZA923557B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70074091A 1991-05-15 1991-05-15

Publications (1)

Publication Number Publication Date
ZA923557B true ZA923557B (en) 1993-11-15

Family

ID=24814683

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA923557A ZA923557B (en) 1991-05-15 1992-05-15 Composition of angiotensin-II receptor antagonists and calcium channel blockers

Country Status (11)

Country Link
EP (1) EP0584250A1 (xx)
JP (1) JP2930252B2 (xx)
AU (1) AU664375B2 (xx)
CA (1) CA2103276A1 (xx)
CZ (1) CZ281570B6 (xx)
IE (1) IE921534A1 (xx)
IL (1) IL101858A (xx)
MX (1) MX9202243A (xx)
NZ (1) NZ242724A (xx)
WO (1) WO1992020342A1 (xx)
ZA (1) ZA923557B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
JP3883205B2 (ja) * 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
DE69626958T2 (de) 1995-03-16 2004-03-18 Pfizer Inc. Verwendung von amlodipin, eines seiner salze oder felodipin in kombination mit einem ace-hemmer zur herstellung eines arzneimittels zur behandlung von nicht ischämischer kongestiver herzinsuffizienz
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
DE69936992T2 (de) 1998-07-10 2008-03-06 Novartis Pharma Ag Bluthochdruckgegenmittelkombination des valsartan und kalziumkanal blocker
US7481803B2 (en) * 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
WO2001082858A2 (de) * 2000-05-04 2001-11-08 Ipf Pharmaceuticals Gmbh Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen
CA2430924A1 (en) * 2000-12-01 2002-06-06 Novartis Ag Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP3045174A1 (en) * 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
TW200833325A (en) * 2006-12-26 2008-08-16 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising ascorbic acid
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
EP0565634B1 (en) * 1990-12-14 1999-03-17 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions

Also Published As

Publication number Publication date
CZ281570B6 (cs) 1996-11-13
AU2026992A (en) 1992-12-30
JPH06508128A (ja) 1994-09-14
AU664375B2 (en) 1995-11-16
IL101858A (en) 1996-08-04
NZ242724A (en) 1994-09-27
JP2930252B2 (ja) 1999-08-03
WO1992020342A1 (en) 1992-11-26
MX9202243A (es) 1992-11-01
CA2103276A1 (en) 1992-11-16
EP0584250A1 (en) 1994-03-02
EP0584250A4 (xx) 1994-03-30
IE921534A1 (en) 1992-11-18
IL101858A0 (en) 1992-12-30
CZ235193A3 (en) 1994-03-16

Similar Documents

Publication Publication Date Title
ZA923557B (en) Composition of angiotensin-II receptor antagonists and calcium channel blockers
GB2276560B (en) Bone cement mixing device
EP0538989A3 (en) Well cement compositions and their use
ZA92990B (en) Calcium channel antagonists and methodology for their identification
SI0838217T1 (en) Cosmetic composition containing neuropeptide Y receptor antagonist
IL99246A0 (en) Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
EP0340765A3 (en) Cement composition for extrusion
IL103621A0 (en) Endothelin receptor antagonists and pharmaceutical compositions containing them
AR243487A1 (es) Cemento mezclado de resistencia realzada, composicion formada a partir del mismo, y procedimiento para realzar su resistencia.
ZA93550B (en) Azabricyclic compounds as calcium channel antagonists
PL311272A1 (en) Antagonists of endotheline receptors
IL99539A0 (en) Fibrinogen receptor antagonists and pharmaceutical compositions containing them
ZA961325B (en) Cement composition
PL310386A1 (en) Antagonists of factor i receptors
BR9407743A (pt) Composiçao oral de peróxido de cálcio-bicarbonato
AU9069191A (en) Use of angiotensin ii receptor antagonists in the prevention of restinosis
AU5449194A (en) Combinations of angiotensin-ii receptor antagonists and diuretics
PL330708A1 (en) Derivatives of indolydine useful as antagonists of 5-ht-2c receptor
GB9105246D0 (en) Cement restrictor
GB9320799D0 (en) Fibrinogen receptor antagonists
GB9324606D0 (en) Angiotensin-ii receptor blocking cycloakylbenzylimidazoles
ZA922265B (en) Somatostatin receptor
IL101368A0 (en) Somatostatin receptor
KR19987002821A (en) Cement composition
ZA924350B (en) Novel cement additives and hydraulic cement mixes containing them